月经期和子宫内膜异位症中循环游离子宫内膜DNA水平不变
本研究前瞻性比较了子宫内膜异位症患者、腹腔镜非内异症医院对照和健康社区对照的循环游离DNA(cirDNA),并比较健康女性月经期与非月经期的子宫内膜cirDNA。结果显示各组总cirDNA和子宫内膜cirDNA均无差异,月经期子宫内膜cirDNA亦无变化;腹腔镜患者cirDNA长片段比例显著高于社区健康对照。
要点
- 子宫内膜cirDNA在月经期不升高,在子宫内膜异位症中也不升高。
- 总cirDNA在健康对照、医院对照和子宫内膜异位症患者间无差异。
- 腹腔镜患者cirDNA大小比值显著高于社区健康对照,提示长片段丰度增加。
核心结论
- 子宫内膜cirDNA在月经期不增加,在子宫内膜异位症中不升高。
- 无证据表明cirDNA可作为子宫内膜异位症的诊断生物标志物。
- 子宫内膜异位症和月经不应影响其他疾病领域(包括肿瘤学)基于甲基化的诊断。
研究设计与样本
- 前瞻性招募经手术确诊的子宫内膜异位症患者59例、无子宫内膜异位症的腹腔镜患者(医院对照)27例,并在大学环境中招募健康社区对照25例。
- 从健康女性中采集36对匹配的非月经期和月经期样本,比较子宫内膜cirDNA。
- cirDNA从静脉血浆中提取,通过定量PCR检测ALU重复元件(115 bp)和TP53基因序列(105 bp)定量总浓度;子宫内膜来源cirDNA通过亚硫酸氢盐转化后对FAM101A区域(69 bp)进行甲基化特异性微滴数字PCR定量;cirDNA片段化比值通过长段ALU重复元件(247 bp)相对115 bp ALU靶标表达量获得。
主要发现
- 平均总cirDNA在健康对照(ALU-115-3.31 ng/ml;TP53-2.73 ng/ml)、医院对照(ALU-115-3.47 ng/ml;TP53-2.83 ng/ml)和子宫内膜异位症患者(ALU-115-3.35 ng/ml;TP53-2.66 ng/ml)间无变化。
- 子宫内膜cirDNA在健康对照(18.3 copies/ml)、医院对照(20.6 copies/ml)和子宫内膜异位症患者(22 copies/ml)间无变化。
- 子宫内膜cirDNA在月经期无变化(非月经期:38 copies/ml;月经期:33 copies/ml)。
- 无论子宫内膜异位症诊断如何,腹腔镜患者(医院对照:0.77;子宫内膜异位症患者:0.79)的cirDNA大小比值显著高于社区招募的健康对照(0.64),表明长cirDNA片段丰度增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 三个队列间的年龄、BMI和产次无法完全匹配,但其中仅年龄已被证明影响循环DNA水平,且在本队列年龄范围内未受影响。
- 社区招募健康女性和腹腔镜女性的血液分别通过肘前静脉穿刺(3小时内处理)和外围套管或静脉穿刺(6小时内处理)采集,可能影响循环DNA片段的大小分布。
- 采集非月经期血样时未区分卵泡期、排卵期和黄体期,因此仅月经期样本在一致阶段采集,其他阶段的cirDNA波动可能掩盖月经期的微小变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is circulating cell-free DNA (cirDNA) from the endometrium elevated during menstruation and in endometriosis? SUMMARY ANSWER: Endometrial cirDNA does not increase during menstruation and is not elevated in endometriosis. WHAT IS KNOWN ALREADY: Changes in cirDNA associated with common benign conditions are a potential source of false positives in cancer diagnostic applications, but also present an opportunity for biomarker development for diseases such as endometriosis. Elevated cirDNA has been reported in endometriosis patients compared to healthy community controls, but no difference in total or endometrial cirDNA has been found between patients with endometriosis and patients with other gynaecological conditions. Likewise, menstruation is a potential driver of changes in cirDNA levels and tissue profile, but total and endothelial cirDNA do not increase during menstruation. STUDY DESIGN, SIZE, DURATION: For endometriosis comparisons, 59 participants with surgically confirmed endometriosis and 27 laparoscopic patients without endometriosis (hospital controls) were prospectively recruited, while 25 healthy community participants (healthy controls) were recruited in a university setting. Total and endometrial cirDNA and cirDNA fragmentation were measured across the three groups. For menstrual comparisons, 36 matched non-menstruating and menstruating samples were collected from healthy women recruited within a university setting, and the endometrial cirDNA was compared between the two groups. PARTICIPANTS/MATERIALS, SETTING, METHODS: cirDNA was extracted from venous blood plasma then quantitated by quantitative PCR of ALU repetitive element (115 bp) and TP53 gene sequence (105 bp) for total concentration. cirDNA derived from the endometrium was quantitated by methylation-specific droplet digital PCR of a FAM101A region (69 bp) after bisulfite conversion of the DNA. A cirDNA size fragmentation ratio was obtained by quantifying a long segment of ALU repetitive element (247 bp) and expressing the amount relative to the 115 bp ALU target. MAIN RESULTS AND THE ROLE OF CHANCE: No differences in cirDNA level were found in any comparison populations in this study. Mean total cirDNA was unchanged between healthy controls (ALU-115-3.31 ng/ml; TP53-2.73 ng/ml), hospital controls (ALU-115-3.47 ng/ml; TP53-2.83 ng/ml) and endometriosis patients (ALU-115-3.35 ng/ml; TP53-2.66 ng/ml). Likewise, endometrial cirDNA was unchanged between healthy controls (18.3 copies/ml), hospital controls (20.6 copies/ml) and endometriosis patients (22 copies/ml). Endometrial cirDNA did not change during menstruation (non-menstruating: 38 copies/ml; menstruating: 33 copies/ml). Irrespective of endometriosis diagnosis, blood from patients undergoing laparoscopy (hospital controls: 0.77; endometriosis patients: 0.79), had a significantly higher cirDNA size ratio than community-recruited healthy controls (0.64), indicating increased abundance of long cirDNA fragments. LIMITATIONS, REASONS FOR CAUTION: It was not possible to completely match the age, BMI and parity between the three cohorts investigated, however of these, only age has been shown to influence circulating DNA levels and not within the age range of our cohort. Blood from community-recruited healthy women and women undergoing laparoscopy was collected via antecubital vein venepuncture (processed within 3 h) and with either peripheral cannula or venepuncture (processed within 6 h), respectively, which could potentially impact the size distribution of circulating DNA fragments. For the collection of non-menstruating phase blood samples, we did not differentiate between follicular phase, ovulation and luteal phase. Thus, only the mensturating samples were collected at a consistent phase, and any fluctuations in cirDNA that occur at the other phases may have obscured small changes during menstruation. WIDER IMPLICATIONS OF THE FINDINGS: There is no evidence that cirDNA has potential as a diagnostic biomarker for endometriosis. Endometriosis, representing a common benign gynaecological condition, and menstruation, representing a normal physiological occurrence in women, should not affect methylation-based diagnostics in other disease areas, including oncology. STUDY FUNDING/COMPETING INTEREST(S): N.L.Y.: Australian Government Research Training Program (RTP) Stipend through The University of New South Wales, Translational Cancer Research Network PhD Scholarship Top-Up Award via the Cancer Institute NSW, Beth Yarrow Memorial Award in Medical Science, UNSW Completion Scholarship; C.E.H.: Gynaecological Oncology Fund of the Royal Hospital for Women; K.W.: Ovarian Cancer Research Foundation and CAMILLA AND MARC. C.E.F.: UNSW Women's Wellbeing Academy and the Australian Human Rights Institute. We declare the following competing interest: K.W. holds stock in Guardant Health, Exact Sciences and Epigenomics AG. No other authors have competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Yuwono NL, Alonso A, Abbott J, et al. Circulating cell-free endometrial DNA level is unaltered during menstruation and in endometriosis. Hum Reprod. 2022. PMID: 36166696. doi:10.1093/humrep/deac198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。